EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

EyePoint Pharmaceuticals reports revenue growth and strategic expansion plans

EyePoint Pharmaceuticals showcased strong revenue growth, promising product pipeline with EYP-1901, and strategic partnerships for future expansion. While facing challenges in trial design and molecule size for sustained release, the company is well-positioned for growth with opportunities for collaborations and improved margins in 2023.

EyePoint Pharmaceuticals reports strong Q1 performance and advances revolutionary eye disease treatment

EyePoint Pharmaceuticals (EYPT) delivered a strong Q1 2023 performance, driven by progress in clinical trials for EYP-1901 and a robust YUTIQ franchise.
The company's focus on innovation, safety, and market needs positions EYP-1901 as a potential game-changer in treating chronic eye diseases.
While challenges exist in trial modifications and regulatory considerations, opportunities abound in market expansion, collaboration potential, and regulatory progress.
Overall, EyePoint Pharmaceuticals (EYPT) showcases promising growth prospects and a commitment to advancing novel treatments for retinal diseases.

EyePoint Pharmaceuticals reports Q2 revenue growth amidst operational challenges

EyePoint Pharmaceuticals' Q2 2023 performance showed revenue growth but with significant operating expenses leading to a net loss.
Strengths lie in the progress of EYP-1901, positive data presentations, and a well-capitalized position for future endeavors.
Challenges include financial losses, concerns about patient response variability, and Phase III trial design complexities.
Opportunities exist in exploring funding avenues, post-approval studies, and strategic cost management for Phase III trials.

EyePoint Pharmaceuticals reports Q3 revenue growth and advances drug pipeline

EyePoint Pharmaceuticals showcased progress in drug development and revenue generation in Q3 2023.
The company is strategically positioned with a strong cash position to fund operations into 2025.
Focus on innovative drug delivery mechanisms and collaborations for sustained release treatments.

EyePoint Pharmaceuticals excels in Q4, poised for retinal disease innovation

EyePoint Pharmaceuticals delivered strong financial results, showcased promising trial outcomes for EYP-1901 in wet AMD, and addressed key analyst inquiries regarding market dynamics and competition. With a focus on innovation and strategic leadership appointments, the company is poised for transformative developments in retinal disease treatments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

As of late, it has definitely been a great time to be an investor in EyePoint.

Will EyePoint Continue to Surge Higher?

WATERTOWN, Mass., Jan.  27, 2020  (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, and Ocumension Therapeutics, a fast-growing ophthalmology focused pharmaceutical company in China, today announced an exclusive license agreement for the development and commercialization of DEXYCU® (dexamethasone intraocular suspension) 9% for the treatment of post-operative inflammation following ocular surgery in Mainland China, Hong Kong, Macau and Taiwan. DEXYCU is currently marketed by EyePoint in the U.S. EyePoint maintains worldwide development and commercialization rights outside of the territories licensed to Ocumension.

EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize DEXYCU® for Post-operative Inflammation in Mainland China, Hong Kong, Macau and Taiwan

EyePoint Pharmaceuticals: Gaining Traction

EyePoint Faces A Big Opportunity

WATERTOWN, Mass., Nov.  19, 2019  (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced an amendment to its existing debt facility with CRG Servicing LLC (CRG). Under the terms of the amendment, CRG has waived the financial covenant associated with the Company’s product revenue of DEXYCU® and YUTIQ® for the twelve-month period ending on December 31, 2019. There were no other changes made to the term loan agreement.

EyePoint Pharmaceuticals Announces Amendment to CRG Debt Facility

EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q3 2019 Results - Earnings Call Transcript

- DEXYCU and YUTIQ now available across the VA and on Federal Supply Schedule to benefit U.S. veterans and other government employees -

EyePoint Pharmaceuticals Announces Addition of DEXYCU® and YUTIQ® to Department of Veteran Affairs Federal Supply Schedule

EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will EyePoint Pharmaceuticals (EYPT) Report Negative Earnings Next Week? What You Should Know

WATERTOWN, Mass., Oct.  02, 2019  (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, announced today that the Company’s permanent and specific J-Code for YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg three-year micro-insert for chronic, non-infectious uveitis affecting the posterior segment of the eye is now in effect. The code, J7314, was issued by the Centers for Medicare and Medicaid Services (CMS) one quarter earlier than under prior CMS policy.

EyePoint Pharmaceuticals Announces Permanent and Specific J-Code for YUTIQ® Now in Effect

WATERTOWN, Mass., Sept.  27, 2019  (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that two abstracts supporting the Company's YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg three-year micro-insert for chronic, non-infectious uveitis affecting the posterior segment of the eye have been accepted for presentation at the American Academy of Ophthalmology (AAO) 2019 Annual Meeting being held October 12 – 15, 2019 in San Francisco, CA. One abstract was accepted for oral presentation at the Retina Subspecialty Day program of AAO on October 11, 2019.

EyePoint Pharmaceuticals Announces YUTIQ® Presentations at the American Academy of Ophthalmology 2019 Annual Meeting

WATERTOWN, Mass., Sept.  26, 2019  (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Nancy Lurker, President and Chief Executive Officer, is scheduled to present at the 2019 Cantor Global Healthcare Conference on Friday, October 4, 2019 at 10:05 AM ET.

EyePoint Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

Dexycu has superior utility over conventional eye drops for the treatment of inflammation post cataract surgery.

Why Investors Have Underestimated EyePoint's Dexycu And Yutiq Growth Potential Since Launch

Catalyst Pharmaceuticals

Forty Seven Inc

These three biotech stocks could be great buys this month.

3 Top Biotech Stocks to Buy in September

WATERTOWN, Mass., Sept.  09, 2019  (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that two abstracts supporting the Company's YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg three-year micro-insert for chronic, non-infectious uveitis affecting the posterior segment of the eye have been accepted for two oral presentations at the 52nd Annual Retina Society Scientific Meeting being held September 11-15, 2019 in London.

EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ® to be Presented at the 52nd Annual Retina Society Scientific Meeting

Kala Pharmaceuticals

Novartis

Ocular Therapeutix

The growing eye industry is something investors can’t ignore.

Keep Your Eye on These 4 Healthcare Stocks

EyePoint Pharmaceuticals has just introduced two new treatments, YUTIQ and DEXYCU, both involve the slow release of steroids to prevent eye infections.

EyePoint Pharmaceuticals Is Eyeing 2 Big Market Opportunities

EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q2 2019 Results - Earnings Call Transcript

EyePoint Pharmaceuticals (EYPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q1 2019 Results - Earnings Call Transcript

A secondary offering raised some cash but diluted current shareholders.

News for EyePoint Pharmaceuticals Stock (EYPT)